- Companies
- Medartis
Medartis Valuation Multiples
Medartis is valued at $1.4B as of October 2026, a 4.0x revenue multiple. In the last 12 months, Medartis revenue was $395M and Medartis EBITDA was $71M.
Medartis Overview
About Medartis
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from EMEA and also has a presence in APAC, LATAM, and USA.
Founded
1997
HQ
Employees
949
Website
Financials (LTM)
EV
$1.6B
Valuation Multiples
Start free trialMedartis Financials
Medartis reported last 12-month revenue of $395M and EBITDA of $71M.
In the same LTM period, Medartis generated $322M in gross profit, $71M in EBITDA, and $17M in net income.
Revenue (LTM)
Medartis P&L
In the most recent fiscal year, Medartis reported revenue of $326M and EBITDA of $54M.
Medartis is profitable as of last fiscal year, with gross margin of 76%, EBITDA margin of 16%, and net margin of 3%.
Financial data powered by Morningstar, Inc.
Medartis Stock Performance
Medartis has current market cap of $1.4B, and enterprise value of $1.6B.
Market Cap Evolution
Medartis' stock price is $109.25.
Medartis share price increased by 8.2% in the last 30 days, and by 7.5% in the last year.
Medartis has an EPS (earnings per share) of $0.81.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.4B | 2.7% | 8.2% | 0.2% | 7.5% | $0.81 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMedartis Valuation Multiples
Medartis trades at 4.0x EV/Revenue multiple, and 22.3x EV/EBITDA.
EV / Revenue (LTM)
Medartis Financial Valuation Multiples
As of October 22, 2026, Medartis has market cap of $1.4B and EV of $1.6B.
Medartis has a P/E ratio of 77.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Medartis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Medartis Margins & Growth Rates
Medartis grew revenue by 25% and EBITDA by 38% in the last fiscal year.
In the most recent fiscal year, Medartis reported gross margin of 76%, EBITDA margin of 16%, and net margin of 3%.
Medartis Margins
Medartis Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Medartis Operational KPIs
Medartis' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
Medartis' Rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medartis' Rule of X is 80% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Medartis Competitors
Medartis competitors include Sansure Biotech, Sinocare, Vitrolife, El.En. Group, Weigao Group, Conmed, Nakanishi, VCANBIO, Beijing Balance Medical and Alpha Tau Medical.
Most Medartis public comparables operate across Medical Devices, DeepTech and HealthTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $246M | $49M | 4.2x | 4.1x | 21.4x | 14.3x | |||
| $698M | $43M | 2.0x | 1.9x | 32.9x | 15.6x | |||
| $347M | ($445M) | 4.1x | 4.0x | (3.2x) | 12.6x | |||
| $663M | $93M | 1.8x | 2.0x | 12.9x | 10.7x | |||
| $228M | $56M | 4.8x | 4.6x | 19.5x | 14.1x | |||
| $1.4B | $176M | 1.6x | 1.6x | 12.5x | 7.9x | |||
| $513M | $53M | 2.5x | 2.2x | 24.7x | 8.5x | |||
| $218M | $44M | 4.6x | 4.3x | 22.5x | 24.9x | |||
This data is available for Pro users. Sign up to see all Medartis competitors and their valuation data. Start Free Trial | ||||||||
Medartis VC Funding History
Before going public, Medartis raised funding across 1 round.
Medartis Funding Rounds
Acquisitions by Medartis
Medartis has acquired 4 companies to date.
Last acquisition by Medartis was on September 17th 2026. Medartis acquired Miami Anatomical Research Center for undisclosed valuation.
Latest Acquisitions by Medartis
| Description | Miami Anatomical Research Center is a research institute that conducts clinical research studies. | Keri Medical is a Lyon, France-based orthopedics firm manufacturing specialized implants and instruments for hand and wrist surgery. Its product line includes plates, screws, and anchors used in trauma repair, arthritis treatment, and reconstructive procedures by surgeons worldwide. | - | Mimedis is a Basel, Switzerland-headquartered medical device company specializing in patient-specific cranial and orthopedic implants using 3D printing and biomaterials. Spun out from FHNW and University Hospital Basel in 2013, it produces custom titanium and PEEK implants for trauma and tumor reconstruction, collaborating with surgeons across Europe. |
| HQ Country | ||||
| HQ City | Miami, FL | Geneva | - | Basel |
| Deal Date | 17 Sep 2026 | 17 Jul 2025 | 7 Mar 2022 | 5 Jul 2017 |
| Valuation | undisclosed | $211M | $70M | undisclosed |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Medartis acquisitions and their M&A valuation multiples. Start Free Trial | ||||
Investments by Medartis
Medartis has invested in 1 company to date.
Latest investment by Medartis was on March 17th 2023. Medartis invested in Keri Medical in their $19M Strategic investment round (EV/Revenue multiple available to Pro users).
Latest Investments by Medartis
| Description | Keri Medical is a Lyon, France-based orthopedics firm manufacturing specialized implants and instruments for hand and wrist surgery. Its product line includes plates, screws, and anchors used in trauma repair, arthritis treatment, and reconstructive procedures by surgeons worldwide. |
| HQ Country | |
| HQ City | Geneva |
| Deal Date | 17 Mar 2023 |
| Round | Strategic investment |
| Raised | $19M |
| Investors | Medartis |
| Valuation | $41M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Medartis investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Medartis
| When was Medartis founded? | Medartis was founded in 1997. |
| Where is Medartis headquartered? | Medartis is headquartered in Switzerland. |
| How many employees does Medartis have? | As of today, Medartis has over 949 employees. |
| Is Medartis publicly listed? | Yes, Medartis is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Medartis? | Medartis trades under MED ticker. |
| When did Medartis go public? | Medartis went public in 2018. |
| Who are competitors of Medartis? | Medartis main competitors include Sansure Biotech, Sinocare, Vitrolife, El.En. Group, Weigao Group, Conmed, Nakanishi, VCANBIO, Beijing Balance Medical, Alpha Tau Medical. |
| What is the current market cap of Medartis? | Medartis' current market cap is $1.4B. |
| What is the current revenue of Medartis? | Medartis' last 12 months revenue is $395M. |
| What is the current revenue growth of Medartis? | Medartis revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of Medartis? | Current revenue multiple of Medartis is 4.0x. |
| What is the current EBITDA of Medartis? | Medartis' last 12 months EBITDA is $71M. |
| What is Medartis' EBITDA margin? | Medartis' last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Medartis? | Current EBITDA multiple of Medartis is 22.3x. |
| What is the current FCF of Medartis? | Medartis' last 12 months FCF is $1M. |
| What is Medartis' FCF margin? | Medartis' last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of Medartis? | Current FCF multiple of Medartis is 1110.0x. |
| How many companies Medartis has acquired to date? | As of October 2026, Medartis has acquired 4 companies. |
| What was the largest acquisition by Medartis? | $211M acquisition of Keri Medical on 17th July 2025 was the largest M&A Medartis has done to date. |
| What companies Medartis acquired? | Medartis acquired Keri Medical, Nextremity Solutions, Miami Anatomical Research Center, and Mimedis. |
| In how many companies Medartis has invested to date? | As of October 2026, Medartis has invested in 1 company. |
| What was the last Medartis investment? | On 17th March 2023 Medartis invested in Keri Medical, participating in a $19M Strategic investment round at $41M valuation. |
| In what companies Medartis invested in? | Medartis invested in Keri Medical. |
See public comps similar to Medartis
Lists including Medartis
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




